Anzeige
Mehr »
Samstag, 07.03.2026 - Börsentäglich über 12.000 News
USA erklären Kupfer zur Chefsache - dieser Nevada-Explorer bohrt bereits
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche
PR Newswire
245 Leser
Artikel bewerten:
(1)

Dalton Pharma Services Invests in Robotic Aseptic Powder Fill-Finish Line from 3P innovation

TORONTO, June 5, 2024 /PRNewswire/ -- Pharmaceutical manufacturing company, Dalton Pharma Services (a Seikagaku Group company), has recently commissioned 3P innovation (Warwick, UK) to design and construct a fully automated state-of-the-art high-speed aseptic powder filling line to expedite the delivery of drugs to market in a more compliant, efficient, and economical manner.

Dalton Pharma Services and 3P innovation Logos

In line with Dalton's ongoing mission to adopt cutting-edge technology, this strategic investment not only expands the collaboration between the two organisations, but it also enables Toronto-based Dalton to effectively meet its current and future business needs. Furthermore, this venture solidifies 3P innovation's position as global leaders in the supply of aseptic filling technology.

Jixing Wang, President at Dalton, commented: "Due to increasing customer demand, we needed to further enhance our competencies in speed, quality and flexibility. Having maximised our capacity in aseptic powder fill/finish, we sought innovative technology to support our growth. This investment will reinforce Dalton's market position as a leading partner in aseptic powder filling."

Dalton identified the Robotic Fill-Finish (RFF) Cell from 3P innovation as being an ideal solution based on the feasibility studies of several difficult to handle powders. Other factors of consideration included the increased sterility assurance, reduced risk of product failure and enhanced compliance with Annex 1.

The current agreement builds on a multi-year association between the two companies. "Both 3P and Dalton share a similar mindset," notes Chris Kotoris, Senior Director of Operations at Dalton: "We are very much focused on finding solutions to our client's challenges whilst being nimble enough to adapt and influential enough to lead. The innovative technology of 3P innovation combined with Dalton's cGMP facility and expertise are your perfect partners."

The acquisition of 3P innovation's RFF Cell enables Dalton to address larger segments of the pharmaceutical market and serve customers with greater global patient populations.

The new system comprises fully integrated isolators with multiple linked process chambers that have been designed to provide a compact integrated solution for ready-to-use (RTU) tubs. Benefiting from six chambers, filling, stoppering, capping and crimping will all be done automatically. "What's unique about this project," said Nick Brooks, Managing Director at 3P innovation, "is that the line has been built from the ground up with Annex 1 compliance in mind. We are not just updating legacy equipment, here, this is a bespoke creation."

"After 10 years of integrating fill lines into third-party isolators and being frustrated by the challenges of working with plant designed by others, we decided to build our own." The result is a compact, fully contained unit that enables super-fast site integration with zero civil structural work required to install the unit into existing cleanroom environments. Technically able to handle both powder and liquid media filling applications, 3P innovation is delighted that the first commercial unit has been sold and is currently under construction.

About 3P innovation

3P innovation is a dynamic engineering company and UK's leading supplier of automated fill-finish equipment. With more than 1000 years of combined engineering experience, our pharmaceutical equipment portfolio is designed to support customers throughout the different phases of their product's lifecycle, whether that's early-stage drug development or commercial-scale production equipment.

About Dalton Pharma Services

Dalton Pharma Services is a leading North American cGMP pharmaceutical organisation providing integrated drug discovery, development, and manufacturing services. Dalton is US FDA-inspected, Health Canada-licensed and brings more than 35 years of experience to every project. We deliver fully integrated solutions with an emphasis on speed, flexibility, and quality.

Robotic Fill Finish (RFF) Cell- 3P/Dalton

Logo - https://mma.prnewswire.com/media/2430399/Dalton_Pharma_Services_and_3P_innovations_Logo.jpg

Photo - https://mma.prnewswire.com/media/2430400/3P_innovation_R_series.jpg

Cision View original content:https://www.prnewswire.co.uk/news-releases/dalton-pharma-services-invests-in-robotic-aseptic-powder-fill-finish-line-from-3p-innovation-302163964.html

© 2024 PR Newswire
Favoritenwechsel - diese 5 Werte sollten Anleger im Depot haben!
Das Börsenjahr 2026 ist für viele Anleger ernüchternd gestartet. Tech-Werte straucheln, der Nasdaq 100 tritt auf der Stelle und ausgerechnet alte Favoriten wie Microsoft und SAP rutschen zweistellig ab. KI ist plötzlich kein Rückenwind mehr, sondern ein Belastungsfaktor, weil Investoren beginnen, die finanzielle Nachhaltigkeit zu hinterfragen.

Gleichzeitig vollzieht sich an der Wall Street ein lautloser Favoritenwechsel. Während viele auf Wachstum setzen, feiern Value-Titel mit verlässlichen Cashflows ihr Comeback: Telekommunikation, Industrie, Energie, Pharma – die „Cashmaschinen“ der Realwirtschaft verdrängen hoch bewertete Hoffnungsträger.

In unserem aktuellen Spezialreport stellen wir fünf Aktien vor, die genau in dieses neue Marktbild passen: solide, günstig bewertet und mit attraktiver Dividende. Werte, die nicht nur laufende Erträge liefern, sondern auch bei Marktkorrekturen Sicherheit bieten.

Jetzt den kostenlosen Report sichern – bevor der Value-Zug 2026 endgültig abfährt!

Dieses exklusive PDF ist nur für kurze Zeit gratis verfügbar.
Werbehinweise: Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.